CLSDQ
CLEARSIDE BIOMEDICAL INC
stock OTC

Sharing a five-stock healthcare watchlist I’m tracking into 2026.
Each name approaches healthcare from a different angle, and at this stage, progress tends to show up through concrete milestones adoption, data, approvals, or platform validation.
Here’s what puts each one on my radar and what the next meaningful catalyst looks like.
**1) AIML Innovations Inc.**
*CSE: AIML | OTCQB: AIMLF*
Market cap: \~CA$8–10M
Price: \~CA$0.035–0.04
AI-driven ECG analysis designed for high-volume cardiac workflows. AIML’s signal-first software is built to scale as ECG usage expands, with efficiency gains translating directly into operating leverage.
Catalysts to watch:
* Expansion of commercial ECG deployments
* New hospital or clinic contracts
* Regulatory progress in Canada and the U.S.
* Evidence of routine, day-to-day clinical use
**2) Oncolytics Biotech**
*TSX: ONC | NASDAQ: ONCY*
Market cap: \~US$90–120M
Price: \~US$0.90–1.30
Clinical-stage oncology biotech developing an immunotherapy platform intended to work alongside existing cancer treatments, which broadens relevance across indications.
Catalysts to watch:
* Clinical trial data updates
* Progress in combination-therapy studies
* Partner or trial-expansion announcements
**3) Sernova Corp.**
*TSXV: SVA | OTCQX: SEOVF*
Market cap: \~CA$45–50M
Price: \~CA$0.13–0.16
Cell-based therapies delivered via implantable systems, targeting chronic diseases such as diabetes. This blends biology with engineered delivery.
Catalysts to watch:
* Clinical trial updates on Cell Pouch performance
* Expansion into additional therapeutic indications
* Regulatory engagement milestones
**4) Electromed Inc.**
*NYSE American: ELMD*
Market cap: \~US$220–250M
Price: \~US$25–30
Respiratory medical devices used in chronic pulmonary care, supported by prescriptions and reimbursement-driven adoption. This is a steadier medtech cadence.
Catalysts to watch:
* Quarterly sales growth and margin updates
* Broader insurance coverage and reimbursement trends
* Increased penetration in chronic care settings
**5) Clearside Biomedical**
*OTC: CLSDQ*
Market cap: \~US$4–6M
Price: \~US$1.00–1.25
Drug-delivery technology for ophthalmology, focused on improving how therapies reach the eye. A platform approach that supports multiple treatments.
Catalysts to watch:
* Progress in restructuring or asset outcomes
* Any updates on business continuity or platform value
* Changes in trading liquidity or structure
**How I’m following this list**
I’m looking for measurable progress over time, not single announcements. That means tracking whether deployments expand beyond early sites, whether clinical programs advance through clear stages, and whether platforms show signs of durability. At this size, steady follow-through often matters more than speed, and consistency tends to separate durable stories from short-lived ones.
I also revisit the list as milestones are met or missed, adjusting weightings based on execution rather than short-term price movement.
**Closing thoughts**
Healthcare stories at this stage tend to evolve unevenly, but meaningful progress usually leaves a trail. I’m focused on following that trail and letting milestones, adoption, and data guide decisions over the course of 2026.
Always open to other small-cap healthcare names worth tracking into 2026.

Sharing a five-stock healthcare watchlist I’m tracking into 2026.
Each name approaches healthcare from a different angle, and at this stage, progress tends to show up through concrete milestones adoption, data, approvals, or platform validation.
Here’s what puts each one on my radar and what the next meaningful catalyst looks like.
**1) AIML Innovations Inc.**
*CSE: AIML | OTCQB: AIMLF*
Market cap: \~CA$8–10M
Price: \~CA$0.035–0.04
AI-driven ECG analysis designed for high-volume cardiac workflows. AIML’s signal-first software is built to scale as ECG usage expands, with efficiency gains translating directly into operating leverage.
Catalysts to watch:
* Expansion of commercial ECG deployments
* New hospital or clinic contracts
* Regulatory progress in Canada and the U.S.
* Evidence of routine, day-to-day clinical use
**2) Oncolytics Biotech**
*TSX: ONC | NASDAQ: ONCY*
Market cap: \~US$90–120M
Price: \~US$0.90–1.30
Clinical-stage oncology biotech developing an immunotherapy platform intended to work alongside existing cancer treatments, which broadens relevance across indications.
Catalysts to watch:
* Clinical trial data updates
* Progress in combination-therapy studies
* Partner or trial-expansion announcements
**3) Sernova Corp.**
*TSXV: SVA | OTCQX: SEOVF*
Market cap: \~CA$45–50M
Price: \~CA$0.13–0.16
Cell-based therapies delivered via implantable systems, targeting chronic diseases such as diabetes. This blends biology with engineered delivery.
Catalysts to watch:
* Clinical trial updates on Cell Pouch performance
* Expansion into additional therapeutic indications
* Regulatory engagement milestones
**4) Electromed Inc.**
*NYSE American: ELMD*
Market cap: \~US$220–250M
Price: \~US$25–30
Respiratory medical devices used in chronic pulmonary care, supported by prescriptions and reimbursement-driven adoption. This is a steadier medtech cadence.
Catalysts to watch:
* Quarterly sales growth and margin updates
* Broader insurance coverage and reimbursement trends
* Increased penetration in chronic care settings
**5) Clearside Biomedical**
*OTC: CLSDQ*
Market cap: \~US$4–6M
Price: \~US$1.00–1.25
Drug-delivery technology for ophthalmology, focused on improving how therapies reach the eye. A platform approach that supports multiple treatments.
Catalysts to watch:
* Progress in restructuring or asset outcomes
* Any updates on business continuity or platform value
* Changes in trading liquidity or structure
**How I’m following this list**
I’m looking for measurable progress over time, not single announcements. That means tracking whether deployments expand beyond early sites, whether clinical programs advance through clear stages, and whether platforms show signs of durability. At this size, steady follow-through often matters more than speed, and consistency tends to separate durable stories from short-lived ones.
I also revisit the list as milestones are met or missed, adjusting weightings based on execution rather than short-term price movement.
**Closing thoughts**
Healthcare stories at this stage tend to evolve unevenly, but meaningful progress usually leaves a trail. I’m focused on following that trail and letting milestones, adoption, and data guide decisions over the course of 2026.
Always open to other small-cap healthcare names worth tracking into 2026.